Caring Ambassadors Hepatitis C Program Newsletter

August 2009


Clinical Trials, Cohort Studies, Pilot Studies


Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

McHutchison JG, Lawitz EJ, Shiffman ML, et al. N Engl J Med. 2009 Jul 22. [Epub ahead of print]


Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C. Ogawa K, Hige S, Nakanishi M, et al. Antivir Ther. 2009;14(4):513-22.


Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. Arase Y, Suzuki F, Suzuki Y, et al. J Med Virol. 2009 Jul 21;81(9):1584-1590. [Epub ahead of print]


Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Martinot-Peignoux M, Maylin S, Moucari R, et al. Antivir Ther. 2009;14(4):501-11.


Morphometric analysis of hepatic steatosis in chronic hepatitis C infection. Zubair A, Jamal S, Mubarik A. Saudi J Gastroenterol. 2009 Jan;15(1):11-4.


Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Elefsiniotis IS, Vezali E, Mihas K, Saroglou G. : Intervirology. 2009 Jul 14;52(5):247-251. [Epub ahead of print]


Hepatic iron, serum ferritin, HFE mutation, and hepatic fibrosis in chronic hepatitis C.

Won JE, Jeong SH, Chung JI, Lee JH, Hwang SH, Kim JW, Lee SH, Kim N, Park YS, Lee DH, Kim H. Intervirology. 2009 Jul 14;52(5):239-246. [Epub ahead of print]

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Suzuki F, Akuta N, Suzuki Y, et al. Hepatol Res. 2009 Jul 10. [Epub ahead of print]


Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients. Henderson WA, Shankar R, Feld JJ, Hadigan CM. Pediatr Infect Dis J. 2009 Jul 10. [Epub ahead of print]


Sustained responders have better quality of life and productivity compared  with treatment failures long after antiviral therapy for hepatitis C. John-Baptiste AA, Tomlinson G, Hsu PC, et al. Am J Gastroenterol. 2009 Jun 30. [Epub ahead of print]


Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality. Castellvi P, Navinés R, Gutierrez F, et al. J Clin Psychiatry. 2009 Jun;70(6):817-28.


Serum HCV RNA levels and HCV genotype do not affect insulin resistance in non-diabetic patients with chronic hepatitis C: a multicentre study. Tsochatzis E, Manolakopoulos S, Papatheodoridis GV, et al. Aliment Pharmacol Ther. 2009 Jul 9. [Epub ahead of print]


Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, Ruggiero G. Clin Infect Dis. 2009 Aug 15;49(4):498-506.


Basic and Applied Science, Pre-Clinical Studies


The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1 (-/-) mice. Endres CJ, Moss AM, Govindarajan R, Choi DS, Unadkat JD. J Pharmacol Exp Ther. 2009 Jul 14. [Epub ahead of print]





Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. Wang AG, Lee DS, Moon HB, et al. J Pathol. 2009 Jun 18. [Epub ahead of print]


Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Miyaaki H, Ichikawa T, Nakao K, et al. Hepatol Res. 2009 Jul 13. [Epub ahead of print]


FOXP3+ expression in hepatitis C virus specific CD4+ T cells during acute hepatitis C.

Heeg MH, Ulsenheimer A, Grüner NH, et al. Gastroenterology. 2009 Jul 10. [Epub ahead of print]


Specific activation of 2'-5'oligoadenylate synthetase gene promoter by hepatitis C virus-core protein: a potential for developing hepatitis C virus targeting gene therapy. Wang Y, Mao SS, He QQ, Zi Y, Wen JF, Feng DY.


HIV/HCV Coinfection


Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Liver Int. 2009 Jul 7. [Epub ahead of print]


Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. Eyre NS, Phillips RJ, Bowden S, Yip E, Dewar B, Locarnini SA, Beard MR. J Hepatol. 2009 Jun 3. [Epub ahead of print]


Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function. Lapinski TW, Parfieniuk A, Rogalska-Plonska M, Czajkowska J, Flisiak R. Liver Int. 2009 Jul 7. [Epub ahead of print]


Sustained virological response to interferon plus ribavirin reduces liver-related compli-cations and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Berenguer J, Alvarez-Pellicer J, Martín PM, et al. Hepatology. 2009 Jul 2. [Epub ahead of print]

Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.  Angeli E, Mainini A, Cargnel A, et al. Curr HIV Res. 2009 Jul;7(4):447-55.


Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, et al. Clin Infect Dis. 2009 Aug 15;49(4):612-22.


Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Schulze Zur Wiesch J, Pieper D, Stahmer I, et al. Clin Infect Dis. 2009 Aug 1;49(3):466-72.


Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. Morsica G, Bagaglio S, Cicconi P, et al. J Acquir Immune Defic Syndr. 2009 Aug;51(5):574-581.


Epidemiology, Diagnostics, and Miscellaneous Works


Safe using messages may not be enough to promote behaviour change amongst injecting drug users who are ambivalent or indifferent towards death. Miller PG. Harm Reduct J. 2009 Jul 25;6(1):18. [Epub ahead of print]


Visualizing hepatitis C virus infections in human liver by two-photon microscopy.

Liang Y, Shilagard T, Xiao SY, et al. Gastroenterology. 2009 Jul 23. [Epub ahead of print]


Evaluation of the Abbott IUO RealTime HCV Assay and comparison to the Roche TaqMan HCV Analyte Specific Reagent. Pyne MT, Konnick EQ, Phansalkar A, Hillyard DR. J Clin Microbiol. 2009 Jul 22. [Epub ahead of print]


Non-conventional transmission of hepatitis C: a true possibility ignored. Hyder Q, Burhan-ul-Haq M, Rashid R, Qazi S, Mehmood S, Hadi SF. J Pak Med Assoc. 2009 Jul;59(7):430-3.

New and experimental therapies for HCV. Pereira AA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):403-11.


Seroepidemiology of hepatitis C antibodies among dentists and their self-reported use of infection control measures. Ashkenazi M, Fisher N, Levin L, Littner MM. Community Dent Health. 2009 Jun;26(2):99-103.


Viral hepatitis in a homeless shelter in Hawai'i. Boyce DE, Tice AD, Ona FV, Akinaka KT, Lusk H. Hawaii Med J. 2009 Jun;68(5):113-5.


Living with hepatitis C and treatment: the personal experiences of patients. Sgorbini M, O'Brien L, Jackson D. J Clin Nurs. 2009 Aug;18(16):2282-91.